WEP Clinical (WEP) announced today that it has entered into a partnership with BTG Specialty Pharmaceuticals (BTG), a division of Boston Scientific. Under the terms of the partnership, WEP will manage the exclusive distribution of BTG’s rescue medicine, Voraxaze® (glucarpidase), in the UK, European Union (EU) and European Economic Area (EEA) market.

Voraxaze® is approved in the USA and is the first and only drug approved to reduce toxic plasma methotrexate levels. Voraxaze® is a carboxypeptidase which breaks down methotrexate into active metabolites which are then eliminated from the body through organs other than the kidney (primarily the liver).

WEP will utilize its expertise in Named Patient medicine supply to distribute this much-needed drug to patients within the EU as an unlicensed medicine.

WEP will also support BTG with its market access and launch strategy for Voraxaze® in key European territories, following the submission of its planned Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA). Following EMA approval, WEP will market and promote Voraxaze® within the key European territories through its specialist field force.

“This partnership with BTG fully demonstrates WEP Clinical’s commitment to supporting industry in making life-saving treatments available to patients in need around the world”, said Jas Khera, Managing Director EU, WEP Clinical.  “We have worked hard to ensure the appropriate infrastructure and processes are in place to allow for effective and timely distribution and we have dedicated in-house teams ready to put their all behind this new program.”

“We look forward to working with BTG to maximize the potential of Voraxaze, from early named patient sales, right through to product approval and EU commercialization.”

About WEP Clinical

Established in 2008, WEP is a specialist pharmaceutical services company that works with sponsors to help patients and physicians gain access to medicines when there is no treatment available in their country. WEP Clinical is a global organisation and possesses all necessary licenses required to meet drug access and distribution needs across all regions, worldwide.

About BTG Specialty Pharmaceuticals

BTG Specialty Pharmaceuticals, a division of Boston Scientific, provides rescue medicines typically used in emergency rooms and intensive care units to treat patients for whom there are limited treatment options. We are dedicated to the development, manufacture, and commercialization of quality medicines that make a real difference to patients and their families. Our current portfolio of antidotes counteracts certain snake venoms and the toxicity associated with some heart and cancer medications. To learn more, please visit: btgsp.com.